Answers are grounded in this paper and cite their sources.
Cholangiocarcinoma (CCA) is a highly invasive malignant tumor with complex bile composition. Here, we investigate the molecular mechanism by which the bile exosome-derived TTYH3 drives CCA progression and explore the therapeutic potential of targeting TTYH3. TTYH3 expression was examined in exosomes from CCA cell lines and patient bile. Cellular functional assays and nucleoplasmic fractionation assessed TTYH3 nuclear translocation. The 5-methylcytosine (m5C)-bisulfite sequencing, dual-luciferase reporter assays were performed to screen the potential target of TTYH3. Xenograft, lung metastasis, and liver orthotopic models were used to evaluate the role of TTYH3 in metastasis and angiogenesis. High-throughput screening identified a TTYH3-specific inhibitor. We found that CCA cell-derived and bile exosomes containing TTYH3 significantly promoted metastasis and angiogenesis in vitro and in vivo . TTYH3 translocated to the nucleus via KPNB1 and increased NOP2 protein levels by inhibiting its ubiquitination. Nuclear TTYH3 regulated mRNA stability of TAZ via NOP2-mediated m5C modification, promoting CCA metastasis. Telmisartan inhibited TTYH3 expression and effectively suppressed its oncogenic functions. TTYH3 translocate to nuclear by KPNB1 and promote CCA metastasis through NOP2-mediated m5C modification of TAZ . Bile exosome TTYH3 could be a potential biomarker for CCA. Telmisartan targeting TTYH3 could be a potential CCA inhibitor.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: